title: Immunogenicity of next-generation HPV vaccines in non-human primates: Measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine.
abstract: Human papillomavirus (HPV) infection is the most common sexually transmitted disease worldwide. HPVs are oncogenic small double-stranded DNA viruses that are the primary causal agent of cervical cancer and other types of cancers, including in the anus, oropharynx, vagina, vulva, and penis. Prophylactic vaccination against HPV is an attractive strategy for preventing cervical cancer and some other types of cancers. However, there are few safe and effective vaccines against HPV infections. Current first-generation commercial HPV vaccines are expensive to produce and deliver. The goal of this study was to develop an alternate potent HPV recombinant L1-based vaccines by producing HPV virus-like particles into a vaccine that is currently used worldwide. Live attenuated measles virus (MV) vaccines have a well-established safety and efficacy record, and recombinant MV (rMV) produced by reverse genetics may be useful for generating candidate HPV vaccines to meet the needs of the developing world. We studied in non-human primate rMV-vectored HPV vaccine in parallel with a classical alum adjuvant recombinant HPV16L1 and 18L1 protein vaccine produced in Pichia pastoris. A combined prime-boost approach using both vaccines was evaluated, as well as immune interference due to pre-existing immunity against the MV. The humoral immune response induced by the MV, Pichia-expressed vaccine, and their combination as priming and boosting approaches was found to elicit HPV16L1 and 18L1 specific total IgG and neutralizing antibody titres. Pre-existing antibodies against measles did not prevent the immune response against HPV16L1 and 18L1.
authors: Department of Virology, Vaccine Technology Centre, Cadila Healthcare Ltd., Ahmedabad, India; Etna Biotech S.r.l., Stradale Vincenzo Lancia 57, 95121 Catania, Italy; Amity Institute of Virology and Immunology, Amity University, Noida, India. Electronic address: drgaurav123@gmail.com.
authors: Gaurav
authors: G
authors: Gupta
authors: Etna Biotech S.r.l., Stradale Vincenzo Lancia 57, 95121 Catania, Italy. Electronic address: viviana.giannino@etnabiotech.it.
authors: Viviana
authors: V
authors: Giannino
authors: Amity Institute of Virology and Immunology, Amity University, Noida, India.
authors: Narayan
authors: N
authors: Rishi
authors: Department of Virology, Vaccine Technology Centre, Cadila Healthcare Ltd., Ahmedabad, India; Etna Biotech S.r.l., Stradale Vincenzo Lancia 57, 95121 Catania, Italy.
authors: Reinhard
authors: R
authors: Glueck
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D036022:Capsid Proteins / Q000276:immunology; D056724:Immunity, Humoral; D000071497:Immunogenicity, Vaccine; D007074:Immunoglobulin G / Q000097:blood; D008253:Macaca mulatta; D008459:Measles virus; D009856:Oncogene Proteins, Viral / Q000276:immunology; D053918:Papillomavirus Vaccines / Q000145:classification* / Q000276:immunology*; D010843:Pichia; D011994:Recombinant Proteins / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D036022:Capsid Proteins; D007074:Immunoglobulin G; D009856:Oncogene Proteins, Viral; D053918:Papillomavirus Vaccines; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; C063317:L1 protein, Human papillomavirus type 16; C480565:L1 protein, Human papillomavirus type 18
keywords: HPV16L1; HPV18L1; Pichia expressed; Prophylactic vaccine; Recombinant measles